46 results about "Estrous cycle" patented technology

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

The invention discloses a method for constructing a polycystic ovarian syndrome (PCOS) rat model with reduced sex hormone binding globulin (SHBG) on the basis of ruminococcus aureus with the preservation number of ATCC29149, and belongs to the technical field of animal models. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the dosage is 0.2-1 mL / 100 g, the intragastric administration frequency is one time per day to two times per week, and the time lasts for 4-8 weeks, such that the SHBG synthesis of the rat liver is induced to decrease, and the PCOS pathological characteristics such as testosterone level increase, estrus cycle disorder, ovarian polycystic change, insulin resistance and the like are initiated; the problem that a traditional hormone induction method does not conform to the physiological status is solved, the modeling period of a high-fat diet induction method is shortened, and an efficient experimental tool is provided for PCOS mechanism research and drug development.

The invention belongs to the field of animal model construction, and particularly relates to application of an NFATC2IP gene knockout mouse model. Experiments prove that after the NFATC2IP gene is knocked out, the mouse has the characteristic changes of ovarian weight reduction, volume reduction, estrus cycle disorder, fertility reduction, AMH reduction, FSH increase and the like. It is indicated that the NFATC2IP gene is a key factor for maintaining ovarian reserve and endocrine balance, and an NFATC2IP gene knockout mouse can be used for revealing the occurrence mechanism of ovarian dysfunction and can also be used for screening of novel ovarian protection drugs, research of a hormone regulation mechanism and discovery and verification of biomarkers.

The present invention relates to the field of image recognition and judgment technology, and in particular to a method for judging the estrous cycle of rats based on image recognition. Its technical solution includes sample collection and preparation, image collection and optimization, cell segmentation and positioning, feature extraction and analysis, cell classification and recognition, and result verification and feedback. The present invention significantly improves the efficiency and accuracy of morphological recognition of rat vaginal exfoliated cells through systematic and precise operations. From precise sample collection and image acquisition optimization, to multi-dimensional feature extraction and integrated learning classification, and then to result verification and feedback, the scientific nature of recognition is fully guaranteed, which not only greatly shortens the detection time and reduces manual errors, but also continuously improves performance through dynamic optimization, providing efficient and reliable technical support for the study of the estrous cycle of rats.

The invention describes pharmaceutical compositions comprising mirtazapine (MTZ) and venlafaxine (VLF) which exhibit an effective antidepressant effect and at the same time do not alter normal sexual behavior. The administration of the compositions of the invention in animal models, was effective in generating an antidepressant effect without altering the normal sexual behavior of males, while in female rats it did not modify their normal estrous cycle. Likewise, the compositions of the invention further comprise the combination of low doses of mirtazapine and venlafaxine, which allows them to be a promising therapeutic option for patients with depression, since they do not produce adverse effects on sexual behavior.

The invention discloses a cattle herd oestrus prediction method based on time sequence deep learning, which comprises the following steps: collecting multi-source time sequence data of body temperature, motion steps, behavior tags and abnormal events, and constructing a first channel value sequence and a second channel event sequence; on the basis of a double-channel cross attention mechanism, time-dependent modeling is carried out on the two channels through parallel GRU, and behavior event information from the second channel is fused with the first channel as a query vector; based on a memory enhanced time sequence network, performing attention matching on the current fused time sequence representation and a historical estrus cycle vector set, and extracting a key historical memory fragment; current input and historical memory are fused through a gating mechanism, and finally an estrus probability prediction sequence is output through a full-connection neural network. According to the method, accurate identification and intelligent early warning of the oestrus state of the cattle herd are realized, and the multi-source data fusion capability and the time sequence modeling precision are improved.

The invention belongs to the technical field of medical animal disease model modeling, and particularly discloses a dehydroepiandrosterone-induced mouse polycystic ovarian syndrome model under bisphenol A low-dose exposure, specifically, a preparation method of the model comprises the following steps: continuously injecting a mouse for 21 days according to the injection amount of dehydroepiandrosterone of 6mg / 100g; the method comprises the following steps: carrying out intragastric administration on a mouse by using 10 mg / kg of bisphenol A on the 15th day of injection of dehydroepiandrosterone, and continuously carrying out intragastric administration on the mouse for 7 days to obtain the polycystic ovarian syndrome model of the mouse at the childbearing age. According to the mouse model obtained by DHEA modeling at the early stage of adolescence and BPA exposure modeling at the late stage of adolescence, the disordered mood cycle, obesity and high T level are obviously changed; and the human PCOS disease environment and clinical phenotype can be truly simulated.

The invention discloses application of clostridium butyricum based on clostridium butyricum with the product number of BNCC337239 in preparation of a medicine or food for treating and / or preventing polycystic ovarian syndrome, and a culture method of the clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum based on clostridium butyricum. According to the present invention, the bacterial strain is subjected to anaerobic culture to prepare the bacterial liquid, the intragastric administration frequency is 1-3 times per week at the dosage of 0.1-0.5 mL / 100 g, and the intragastric administration lasts for 3-8 weeks, such that the estrus cycle disorder, the insulin resistance, the blood sex hormone disorder and the ovarian polycystic degeneration of the PCOS rat model can be significantly improved, and the method can be used for preparing the drug for treating the polycystic ovarian syndrome.

The Chinese herbal medicine feed additive comprises a formula I and a formula II, the formula I comprises immature bitter orange, roasted rhizoma atractylodis macrocephalae, radix salviae miltiorrhizae, radix astragali, scorched medicated leaven, liquorice root, cowherb seed and akebiaquinata; the formula II comprises astragalus membranaceus, cistanche deserticola, herba epimedii, glossy privet fruit, angelica sinensis, codonopsis pilosula, roasted rhizoma atractylodis macrocephalae, poria cocos and scorched medicated leaven. The invention provides two Chinese herbal medicine feed additives for sows, on one hand, the Chinese herbal medicine feed additives can promote digestion and absorption, promote menstruation and promote lactation; on the other hand, postpartum recovery of sows can be promoted and estrus cycle is shortened; meanwhile, the occurrence of mastitis and other diseases is reduced.

The invention relates to the technical field of livestock breeding, in particular to a digital information management system and method for a breeding cow farm. The method comprises the following steps: acquiring basic data of a cow; the basic data comprises estrus behavior data, pregnancy data and historical breeding data; determining estrus characteristics of each cow according to the estrus behavior data and the historical breeding data; determining a group mating batch according to the estrus characteristics; and according to the pregnancy data, adjusting the batch priority of the group mating batches. By accurately analyzing the oestrus cycle waveform characteristics, pregnancy conditions and historical conception efficiency of cows, division of group mating batches is further optimized, the mating opportunity of each cow is adjusted according to real-time data, the breeding efficiency of the cows is more effectively improved, and sustainable development of the whole breeding industry is promoted.

The invention belongs to the cross technical field of regenerative medicine and traditional Chinese medicine, and discloses a composition for treating premature ovarian failure and a preparation method and application thereof. The composition comprises adult stem cells, traditional Chinese medicine active components consisting of astragaloside and salvianolic acid B in a molar ratio of (1: 1)-(4: 1) and a biodegradable slow-release carrier, and double intervention of'cell repair-microenvironment regulation and control 'is realized through a synergistic strategy of'pretreatment of stem cells by traditional Chinese medicines and targeted slow-release delivery'. Experiments prove that the composition can enable the estrus cycle recovery rate of premature ovarian failure model animals to reach 70%-90% and the number of follicles to be increased by 6-8 times, is obviously superior to the existing single therapy, has a clear mechanism (activating a PI3K / Akt pathway and inhibiting a TGF-beta1 / Smad pathway), and has outstanding clinical transformation value.

The invention relates to application of kaempferol in preparation of drugs, food or health care products for preventing or treating premature ovarian insufficiency diseases caused by chemotherapy drugs. Experiments prove that the estrus cycle disorder of mice exposed to chemotherapeutics can be improved by the administration of the kaempferol; the kaempferol administration can improve the ovarian organ coefficient of the mouse exposed by the chemotherapeutic drug; the administration of kaempferol can effectively improve mouse ovarian hormone level disorder caused by exposure of chemotherapeutic drugs; the kaempferol can increase the number of effect follicles at all levels, reduce the number of atresia follicles and increase the total number of follicles. Experiments prove that kaempferol has a potential value in early-onset ovarian insufficiency caused by chemotherapeutic drugs, and a new method and a new idea are provided for clinical treatment of POI. The method has good popularization and application values.

This invention belongs to the field of biomedicine, and specifically relates to the application of FeTMPyP in the preparation of drugs to alleviate ovarian toxicity. This application addresses the issue that combined exposure to MC-LR and NaNO₂ significantly induces nitrification stress in mouse ovaries, leading to follicular barrier disruption and ovarian reproductive endocrine dysfunction. FeTMPyP was selected as an intervention agent, which effectively alleviated nitrification stress induced by combined exposure to MC-LR and NaNO₂ in mouse ovaries, and improved sex hormone disorders, estrous cycle irregularities, and follicular atresia caused by the combined exposure to these two toxins. Simultaneously, it restored the fertility of mice, indicating that FeTMPyP intervention can alleviate ovarian toxicity induced by combined exposure to MC-LR and NaNO₂ in mice. This invention can be used to prepare drugs to prevent and treat diseases related to ovarian toxicity caused by environmental toxin exposure in mice, providing a new approach for the early identification and targeted intervention of ovarian-related diseases.

The invention relates to the technical field of traditional Chinese medicines, in particular to application of a prepared rehmannia root extract in preparation of a medicine for treating ovarian injury. The inventor finds a single traditional Chinese medicine for treating ovarian injury based on a traditional Chinese medicine compound core medicinal material data mining model. The prepared rehmannia root is taken as a representative core medicinal material screened and output by a model, efficacy verification is carried out in a cyclophosphamide induced ovarian injury mouse model, and the result shows that the prepared rehmannia root can improve E2 and AMH levels, reduce FSH and LH levels, improve orbital cycle disorder and reduce oxidative stress level, so that the prepared rehmannia root can improve the ovarian reserve function of a mouse, and can be used for treating ovarian injury. And a certain improvement effect is achieved on ovarian injury. The invention provides a quantifiable traditional Chinese medicine compound medicinal material screening thought, realizes a closed loop of a method from data mining to efficacy verification, and provides a theoretical basis and an experimental basis for developing novel traditional Chinese medicines for treating ovarian injury.

The invention provides a breeding technology and application of pure-color red cattle, and relates to the technical field of animal breeding. The breeding technology of the pure-color red cattle comprises the following specific steps: S1, detecting an MC1R gene c.901Cgt; a T site and a TYRP1 gene c.1267Ggt; according to a homozygous dominant genotype of a site A, a Gaoligong Mountain small yellow cattle female parent and a Tibetan cattle male parent are screened to ensure that the female parent and the male parent carry homozygous red dominant alleles, and meanwhile, intramuscular fat deposition related gene dominant genotype individuals are selected by combining a whole genome association analysis technology; s2, using prostaglandin F2alpha combined with gonadotropin to release hormone treatment, performing estrus cycle synchronization regulation and control on the Gaoligong Mountain small yellow cattle female parent, implementing regular artificial insemination 24-30 hours after thrombus removal, and using the Tibetan Tibetan cattle frozen semen treated by a sperm screening technology. Pure-color red cattle are bred precisely and directionally by adopting innovative technologies such as gene screening, the meat quality is improved, ecological circulation is achieved, and sustainable development of high-mountain animal husbandry is promoted.

The invention relates to the field of biomedicine, in particular to application of a fructus psoraleae extract and an active ingredient psoralen thereof in preparation of a medicine for treating polycystic ovarian syndrome. According to the invention, a letrozole-induced polycystic ovarian syndrome mouse disease model is constructed, and experiments such as estrus cycle detection, open field experiment, sex hormone ELISA detection and the like are carried out. Experimental results show that the fructus psoraleae extract and the fructus psoraleae can effectively relieve and correct a PCOS mouse estrus cycle disorder state, improve ovarian polycystic change, increase the number of corpus luteum, reduce the number of atresia follicles and cystic follicles, and recover normal ovarian functions and reproductive endocrine disorder. The invention provides a new thought for research and development of medicines for treating polycystic ovarian syndrome.

The invention relates to the technical field of aquaculture, and discloses a breeding method of rana nigromaculata. According to the method, early breeding frogs are adopted as breeding parents, the estrus cycle of the breeding frogs and the development stage of tadpoles are regulated and controlled, the growth cycle of the lateoplexis nigromaculata can be effectively changed, the conventional spawning periods in March and April are staggered, adult frogs with large specifications can be obtained in April, on one hand, goods sources needed by the market can be met for a long time, the market requirements are stabilized, and on the other hand, the market development period is shortened; and on the other hand, the economic benefit of breeding the lateral pleated frogs can be obviously improved.

The invention discloses application of trigonelline or pharmaceutical salt thereof in preparation of a medicine for treating obesity-related polycystic ovarian syndrome. In-vivo experiments prove that the trigonelline has an obvious treatment effect on a polycystic ovarian syndrome rat model, and can be used for treating phlegm-dampness type PCOS rats, recovering the estrus cycle of the rats and reducing fasting blood-glucose and insulin resistance conditions of the rats. More importantly, the trigonelline is small in side effect, free of liver and kidney toxicity and incomparable in safety. In addition, the trigonelline plays a role through a key target GLP-1R. Therefore, the trigonelline can be used for preparing the medicine for treating the obese polycystic ovarian syndrome.

The application is application of cooked panax pseudoginseng in preparation of medicine for treating polycystic ovary syndrome, discloses a new use of cooked panax pseudoginseng, i.e. application of cooked panax pseudoginseng in preparation of medicine for treating polycystic ovary syndrome, and proves that cooked panax pseudoginseng can relieve estrous cycle disorder state of mice, improve polycystic-like change of ovary, increase number of corpus luteum, reduce number of atretic follicle and cystic follicle, and restore normal function of ovary; the application provides a new idea for research and development of medicine for treating polycystic ovary syndrome, and cooked panax pseudoginseng can become a potential candidate medicine for treating polycystic ovary syndrome, and has wide application prospect.

The invention discloses application of maca in preparation of a medicine for improving polycystic ovarian syndrome, and belongs to the field of biological medicine. According to the present invention, letrozole and high-fat feed are adopted to induce and construct a polycystic ovarian syndrome mouse model, and experiments such as estrus cycle detection, ovary and uterus morphology observation, sex hormone detection, blood sugar level detection and the like are performed; results show that the maca can effectively improve the rhythm disorder of the estrus cycle, the polycystic ovarian form and the uterine form of the polycystic ovarian syndrome model mouse, correct the reproductive endocrine disorder, recover the normal ovarian ovulation function and relieve the insulin resistance symptom of the polycystic ovarian syndrome model mouse. A new thought is provided for research and development of medicines for treating the polycystic ovarian syndrome, and maca is expected to become a potential candidate medicine for treating the polycystic ovarian syndrome and has a wide application prospect.

The present invention belongs to the technical field of natural medicine chemistry, and specifically relates to an effective part of Menispermi Rhizoma extract, a preparation method thereof, and an application thereof in the preparation of a drug for preventing or treating polycystic ovary syndrome (PCOS). The effective part of the Menispermi Rhizoma extract is mainly a mixture of daurisoline (DAU) and methyl daurisolate (DAU-Me), and in terms of mass percentage, the proportion is 75%-95%. The effective part of the Menispermi Rhizoma extract provided by the present invention significantly improves the estrous cycle disorder, insulin resistance, blood sex hormone disorder and ovarian polycystic-like changes of PCOS model mice, and does not cause obvious reproductive toxicity, and can be used for the preparation of a drug for preventing or treating polycystic ovary syndrome.

This invention discloses a mixed cell preparation and its application in the preparation of drugs for treating premature ovarian failure. The mixed cell preparation comprises granulosa cells and mesenchymal stem cells, mixed in a certain ratio (preferably 1:1). Granulosa cells are obtained by inducing differentiation from mesenchymal stem cells and express granulosa cell-specific markers (FOXL2, FSHR, etc.), participating in follicular structure reconstruction; mesenchymal stem cells can improve the ovarian microenvironment, inhibit inflammation, and resist fibrosis, providing a suitable "soil" for the survival of granulosa cells. In vitro experiments are expected to show that mixed culture can significantly increase estradiol secretion levels and cell survival rate. Animal models of premature ovarian failure are expected to show that mixed cell therapy can significantly restore the estrous cycle, improve hormone levels, increase the number of follicles at all stages, and improve pregnancy rates, with effects significantly superior to single-cell therapy. This invention utilizes the synergistic effect of the two cell types to achieve dual repair of the "seed" and the "soil," providing a novel treatment strategy for premature ovarian failure.

The application belongs to the technical field of biological medicine, and specifically discloses application of 5-methylcytidine in preparation of a medicine for treating polycystic ovary syndrome, which aims to solve the problem that existing treatment methods are difficult to realize synchronous and coordinated improvement on key pathological phenotypes such as estrous cycle disorder, insulin resistance, and hyperandrogenemia, and the 5-methylcytidine involved is a pyrimidine nucleoside natural product, which is high in safety, low in toxic and side effects, and has unique curative effect in treatment of polycystic ovary syndrome.

The invention relates to the technical field of breeding industry, and particularly discloses a cow feed additive as well as a preparation method and application thereof. The cow feed additive disclosed by the application is prepared from the following components in parts by weight: 5 to 8 parts of herba leonuri, 5 to 8 parts of chestnut shell powder, 1 to 3 parts of lotus root starch, 0.5 to 1.2 parts of soybean zymolyte, 0.01 to 0.05 part of prebiotics, 0.004 to 0.016 part of vitamins and 0.006 to 0.024 part of trace elements. The preparation method of the soybean zymolyte comprises the step of carrying out enzymolysis on soybeans by utilizing an enzymolysis agent, the enzymolysis agent is prepared by mixing beta-mannase and flavourzyme in a weight ratio of (1-5): (0.2-0.8); the prebiotics are formed by mixing cinnamon polysaccharide and bacillus aceticus according to the weight ratio of (7-13): (0.3-0.9). The feed additive provided by the invention is beneficial to shortening the oestrus cycle of cows, and improves the breeding performance of the conception rate of cows and the survival rate of calves at the same time.

The invention discloses a Chinese and Tibetan medicine compound preparation for promoting postpartum recovery of yaks and shortening the estrus cycle as well as a preparation method and application thereof, and belongs to the technical field of Chinese and Tibetan medicines. The traditional Chinese and Tibetan medicine compound preparation is prepared from the following raw materials in parts by weight: 15-20 parts of scutellaria baicalensis, 15-20 parts of Tibetan codonopsis pilosula, 15-20 parts of astragalus membranaceus, 15-20 parts of radix paeoniae alba, 5-10 parts of Tibetan rhizoma polygonati and 5-10 parts of liquorice. After the Chinese and Tibetan medicine compound preparation is applied to postpartum female yaks, the physique of the postpartum female yaks can be enhanced, the oxidation resistance of the postpartum female yaks can be improved, and therefore the effects that the body functions of the postpartum female yaks are recovered, immunity is enhanced, the hormone level is improved, and the estrus cycle is shortened are achieved; the problem of low breeding efficiency caused by insufficient nutrition and severe environment in the traditional breeding process is effectively solved.

The present application belongs to the technical field of pharmaceutical preparations, and specifically relates to the new use of Tongren Wuji Baifeng Pills and a pharmaceutical composition in the preparation of a drug for treating premature ovarian failure, a pharmaceutical preparation comprising Tongren Wuji Baifeng Pills, a method for preparing same, and a method for preparing a drug for treating premature ovarian failure. In the present application, a rat model of chemotherapy-induced premature ovarian failure via intraperitoneal injection of cisplatin and a mouse model of immune-mediated premature ovarian failure via multi-point subcutaneous injection of mouse zona pellucida peptide 3 (pZP3) are established. By means of observing the effects of Tongren Wuji Baifeng Pills on the estrous cycles, organ coefficients, serum sex hormone levels, and ovarian histopathological changes in animals in both models, the therapeutic effect of Tongren Wuji Baifeng Pills on premature ovarian failure is verified and clarified. This expands the new clinical use of the drug and provides a new therapeutic drug and means for treating premature ovarian failure, thereby offering technical support for clinical precision medication.

The present invention relates to the use of Furfurman in the preparation of an anti-radiation drug for the ovary or a drug for treating ovarian ionizing radiation injury. A potential ovarian radiation protector, Furfurman, targeting the Dectin-2 receptor obtained in the present invention was used in animal model experiments. The results showed that it could improve the estrous cycle disorder in irradiated mice, increase the ovarian organ coefficient in irradiated mice, and improve the disorder of ovarian hormone levels in mice caused by irradiation, confirming that Furfurman can reduce radiation-induced ovarian tissue damage and bringing new hope for protecting against ovarian radiation injury.

The invention discloses application of umbilical cord mesenchymal stem cells to treatment of premature ovarian insufficiency. The core is that the umbilical cord mesenchymal stem cells (UC-MSC) are pretreated through TAT-IGF-1R-Wnt3a fusion protein so as to enhance the treatment effect. The fusion protein is formed by connecting a TAT cell-penetrating peptide, an IGF-1R active fragment and a Wnt3a active fragment in series through a flexible linker (G4S) 2, and is obtained through recombinant expression and purification of an escherichia coli expression system. UC-MSC pretreated by the fusion protein is transplanted to a premature ovarian insufficiency (POI) mouse model, so that the orbital cycle disorder of a mouse can be remarkably improved, the serum hormone level (reducing FSH and increasing AMH, E2 and P) can be regulated, the ovarian index can be increased, and the treatment effect of the fusion protein is superior to that of unpretreated UC-MSC and a clinically common estradiol valerate treatment scheme; the invention provides a new clinical treatment strategy for premature ovarian insufficiency, and has important application value.

The invention relates to the field of electrochemical biosensing intelligent detection, in particular to a replacement gilt oestrus monitoring intelligent ear tag based on an estradiol sensor. The replacement gilt oestrus monitoring intelligent ear tag comprises an estradiol detection element, a Bluetooth communication module, an electromagnetic interference detection module, a power supply module, a micro-control unit and a cloud data processing module. The local module rapidly screens suspected oestrus data, 90% of invalid data transmission is reduced, and the network bandwidth requirement of a small-scale farm is lowered; the cloud module performs secondary accurate analysis on suspected data in combination with the historical estrus cycle data and the group estrus characteristics of the sows, so that the judgment precision is ensured, and the cost requirement of a small-scale breeding scene is met.

The invention discloses a novel application of a compound MLN4924 (Pevonedat) in preparation of a medicine for improving oocyte quality and treating related diseases, and belongs to the technical field of biological medicines. PCOS animal model experiments prove that the reproductive endocrine indexes of model animals can be remarkably improved by applying the MLN4924, and the reproductive endocrine indexes are specifically represented by restoring the regularity of an estrus cycle and reducing the levels of testosterone and luteinizing hormone in serum; meanwhile, the fertility is improved, and the birth number is increased. In the aspect of oocyte quality, the treatment can increase the number of normal oocytes in an ovary, improve the first polar body discharge rate of in-vitro maturation of the oocytes and improve the blastocyst formation rate after in-vitro fertilization. A further mechanism research shows that the MLN4924 can inhibit the plasmosis of the TRIM21 in the ovarian granular cells and down-regulate the expression level of the protein of the TRIM21. The results show that the MLN4924 provides a new drug choice for developing related diseases for treating polycystic ovarian syndrome (PCOS) and improving oocyte quality.